Monoammonium glycyrrhizinate

Research use only, not for human use.

Monoammonium glycyrrhizinate is extracted from Such sweet licorice root.

Ammonium glycyrrhizate is a commercial flavorant and emulsifer found in Glycyrrhiza. It inhibits 11β-HSD and is used to treat herpes virus infection. It inhibits viral entry to host cells, prevents glial inflammation and kaninic acid-induced neuronal death, and suppresses DMH-induced carcinogenesis.(In Vivo):The increase of the lung W/D weight ratios is significantly reduced by high and medium dose of MAG (10 and 30mg/kg) administration. Pretreatment with MAG (10 and 30mg/kg) efficiently reduces the production of TNF-?? and IL-1??. MAG (10, 30mg/kg) significantly decreases NF-??B p65 protein expression, compared with LPS. On the contrary, LPS significantly reduces I??B-?? protein expression compared with the control group, whereas MAG (10 and 30mg/kg) significantly increased I??B-?? expression, compared with the LPS group.Low- and high-dose MAG treatment significantly reduces the AST, ALT, TBIL, and TBA levels at 14 and 21 d time points when compared with that of the RIF and INH group, suggesting the protective effect of MAG on RIF- and INH-induced liver injury. MAG treatment groups elevate the hepatic GSH level at 7, 14, and 21 d time points and markedly reduce the MDA level at 14 and 21 d time points in RIF- and INH-treated rats, suggesting the protective effect of MAG in RIF- and INH induced liver injuries.

——

The increase of the lung W/D weight ratios is significantly reduced by high and medium dose of MAG (10 and 30 mg/kg) administration. Pretreatment with MAG (10 and 30 mg/kg) efficiently reduces the production of TNF-α and IL-1β. MAG (10, 30 mg/kg) significantly decreases NF-κB p65 protein expression, compared with LPS. On the contrary, LPS significantly reduces IκB-α protein expression compared with the control group, whereas MAG (10 and 30 mg/kg) significantly increased I??B-?? expression, compared with the LPS group.Low- and high-dose MAG treatment significantly reduces the AST, ALT, TBIL, and TBA levels at 14 and 21 d time points when compared with that of the RIF and INH group, suggesting the protective effect of MAG on RIF- and INH-induced liver injury. MAG treatment groups elevate the hepatic GSH level at 7, 14, and 21 d time points and markedly reduce the MDA level at 14 and 21 d time points in RIF- and INH-treated rats, suggesting the protective effect of MAG in RIF- and INH induced liver injuries.

——

Cytoskeleton/Cell Adhesion Molecules

Akt

Others

Others-Field

——

53956-04-0

839.97

C42H62O16·H3N

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (119.05 mM)

[C@@H]1([C@H]([C@H]([C@@H]([C@H](O1)O[C@H]1[C@H](O[C@@H]([C@H]([C@@H]1O)O)C(=O)O)O[C@@H]1CC[C@@]2([C@@H](C1(C)C)CC[C@@]1([C@@]3(CC[C@@]4(CC[C@@](C[C@@H]4C3=CC(=O)[C@@H]21)(C)C(=O)O)C)C)C)C)O)O)O)C(=O)O.N

(2S,3S,4S,5R,6R)-6-(((2S,3R,4S,5S,6S)-6-carboxy-2-(((3R,4aR,6aR,6bS,8aS,11R,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy)-4,5-dihydroxytetrahydro-2H-pyran-3-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid, ammonia salt

(-20℃)

With Ice Pack

≥ 2 years